EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Combinatory glycoengineering of monoclonal antibodies and its application in cancer therapy: a narrative review

Siyuan Wang, Huairu Tian, Peilin Tian, Yiwen Xing, Yuan Zeng

Translational Cancer Research · 2024-02 · 13 (2) · 1150-1165

DOI: 10.21037/tcr-23-1371 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Translational Cancer Research, 2024-02. Verfasst von Siyuan Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Suzhou Institute for Drug Control, Suzhou, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective: The application of immunotherapy, especially in terms of recombinant monoclonal antibodies (mAbs), is a revolution in the pharmaceutical industry field. Glycosylation plays an essential role in the structures and functions of mAbs, which must be carefully monitored and designed throughout their entire lifespan to ensure safety and efficacy. This review aimed to summarize the current status of the glycoengineering of mAbs for providing reference for the pharmaceutical industry. The application of glycoengineering of mAbs in cancer therapy will also be discussed in this article.

Methods

We searched the PubMed/MEDLINE database to identify studies published between 1970 and 2023 that investigated glycoengineering of recombinant mAbs and its applications. The major findings of these studies were summarized. Key Content and Findings: This article reviews the relationship between glycosylation profiles and antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), shelf-life, and other properties of mAbs. Furthermore, the rational design of glycosylation profiles provides solutions to the unmet needs of new drug development and biosimilar manufacturers. This review also emphatically describes various feasible strategies to optimize the glycosylation pattern in biomanufacturing reported in recent years, especially the approaches of combinatory glycoengineering explored in this field. Finally, we share examples of glycoengineering of mAbs applied in cancer therapy.

Conclusions

Glycan modifications have been achieved through genetic and metabolic glycoengineering. A better understanding of the interplay between cells and the exogenous environment help the combinatorial strategy for glycoengineering in precise control mode. Furthermore, new high-tech approaches for glycoengineering are leading biological engineering and biotherapeutics to a new stage.

Schlagwörter

Stichwörter der Autor:innen

Glycoengineeringcancer therapycombinatory engineeringmonoclonal antibody (mAb)

Autor:innen und Institutionen

  • Suzhou Institute for Drug Control, Suzhou, China.
  • Clinical Pharmacology and Bioanalytics, Development China, Pfizer Pharmaceutical Ltd., Shanghai, China.

Zitieren

APA

Wang, S., Tian, H., Tian, P., Xing, Y., & Zeng, Y. (2024). Combinatory glycoengineering of monoclonal antibodies and its application in cancer therapy: a narrative review. Translational Cancer Research, 13(2), 1150-1165. https://doi.org/10.21037/tcr-23-1371

Vancouver

Wang S, Tian H, Tian P, Xing Y, Zeng Y. Combinatory glycoengineering of monoclonal antibodies and its application in cancer therapy: a narrative review. Translational Cancer Research. 2024;13(2):1150-1165. doi:10.21037/tcr-23-1371

BibTeX
@article{Wang2024,
  author = {Wang, Siyuan and Tian, Huairu and Tian, Peilin and Xing, Yiwen and Zeng, Yuan},
  title = {Combinatory glycoengineering of monoclonal antibodies and its application in cancer therapy: a narrative review},
  journal = {Translational Cancer Research},
  year = {2024},
  volume = {13},
  number = {2},
  pages = {1150--1165},
  doi = {10.21037/tcr-23-1371}
}
Kostenlos starten →